104eP A new prognostic index for patients with advanced biliary tract cancer treated with cisplatin, gemcitabine and durvalumab
M. Persano(University of Cagliari), A. Casadei Gardini(IRCCS Ospedale San Raffaele), Stefano Tamberi(Azienda Unità Sanitaria Locale Della Romagna), Oluseyi Abidoye(Mayo Clinic), M. Rimini(IRCCS Ospedale San Raffaele), Fabian Finkelmeier(Goethe University Frankfurt), Mario Scartozzi(University of Cagliari), J.W. Kim(Seoul National University Bundang Hospital), Lorenzo Fornaro(Azienda Ospedaliera Universitaria Pisana), Silvia Lonardi(University of Brescia), Michele Ferrara(IRCCS Ospedale San Raffaele), Stephen L. Chan(Chinese University of Hong Kong), L. Rimassa(IRCCS Humanitas Research Hospital), Laura Passeri(Vita-Salute San Raffaele University), Hong Jae Chon(CHA University Bundang Medical Center), Arndt Vogel(Princess Margaret Cancer Centre), F. Lo Prinzi(Università Campus Bio-Medico), Changhoon Yoo(Ulsan College), Tatsunari SATAKE(National Cancer Center Hospital East), Silvia Camera(Vita-Salute San Raffaele University)
Cited by 0
Related Papers
Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade
|Journal of Clinical Oncology|2014|2.8k
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2022|1.4k